Istradefylline to Treat Patients with Parkinson's Disease Experiencing "Off" Episodes : A Comprehensive Review
Parkinson's disease (PD) is a common neurodegenerative disorder that leads to significant morbidity and disability. PD is caused by a loss of dopaminergic, cholinergic, serotonergic, and noradrenergic neurons in the central nervous system (CNS), and peripherally; the syndromic parkinsonism symptoms of movement disorder, gait disorder, rigidity and tremor are mostly driven by the loss of these neurons in the basal ganglia. Unfortunately, a significant proportion of patients taking levodopa, the standard of care treatment for PD, will begin to experience a decrease in effectiveness at varying times. These periods, referred to as "off episodes", are characterized by increased symptoms and have a detrimental effect on quality of life and disability. Istradefylline, a novel adenosine A2A receptor antagonist, is indicated as a treatment addition to levodopa/carbidopa in patients experiencing "off episodes". It promotes dopaminergic activity by antagonizing adenosine in the basal ganglia. This review will discuss istradefylline as a treatment for PD patients with off episodes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Neurology international - 12(2020), 3 vom: 08. Dez., Seite 109-129 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Berger, Amnon A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carbidopa |
|---|
| Anmerkungen: |
Date Revised 29.12.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/neurolint12030017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318676982 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318676982 | ||
| 003 | DE-627 | ||
| 005 | 20231225165842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/neurolint12030017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318676982 | ||
| 035 | |a (NLM)33302331 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Berger, Amnon A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Istradefylline to Treat Patients with Parkinson's Disease Experiencing "Off" Episodes |b A Comprehensive Review |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Parkinson's disease (PD) is a common neurodegenerative disorder that leads to significant morbidity and disability. PD is caused by a loss of dopaminergic, cholinergic, serotonergic, and noradrenergic neurons in the central nervous system (CNS), and peripherally; the syndromic parkinsonism symptoms of movement disorder, gait disorder, rigidity and tremor are mostly driven by the loss of these neurons in the basal ganglia. Unfortunately, a significant proportion of patients taking levodopa, the standard of care treatment for PD, will begin to experience a decrease in effectiveness at varying times. These periods, referred to as "off episodes", are characterized by increased symptoms and have a detrimental effect on quality of life and disability. Istradefylline, a novel adenosine A2A receptor antagonist, is indicated as a treatment addition to levodopa/carbidopa in patients experiencing "off episodes". It promotes dopaminergic activity by antagonizing adenosine in the basal ganglia. This review will discuss istradefylline as a treatment for PD patients with off episodes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a carbidopa | |
| 650 | 4 | |a catechol-o-methyl transferase (COMT) | |
| 650 | 4 | |a levodopa | |
| 650 | 4 | |a neurodegenerative | |
| 650 | 4 | |a parkinsonism | |
| 700 | 1 | |a Winnick, Ariel |e verfasserin |4 aut | |
| 700 | 1 | |a Welschmeyer, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Kaneb, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Berardino, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Cornett, Elyse M |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurology international |d 2009 |g 12(2020), 3 vom: 08. Dez., Seite 109-129 |w (DE-627)NLM208279466 |x 2035-8385 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:3 |g day:08 |g month:12 |g pages:109-129 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/neurolint12030017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 3 |b 08 |c 12 |h 109-129 | ||